Primary and Secondary Hemostasis in Elective Coronary Artery Bypass Graft Surgery

Coronary Disease Clinical Trial

— HEMOCOR  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00825981
• Other study ID #: 2008/10DEC/350
• Status: Completed
• Phase: N/A
• First received: January 16, 2009
• Last updated: July 22, 2010
• Start date: January 2009
• Est. completion date: March 2010

Study information

• Verified date: July 2010
• Source: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Patients undergoing elective coronary artery bypass graft surgery (CABG) are treated with platelet inhibitors to reduce myocardial infarction and mortality.However, this can increase perioperative bleeding. A retrospective analysis of the data in our institution has revealed a significant increase in transfusion requirements after elective CABG since 5 years. The aim of our study is to observe if this increase in transfusion requirements is due to platelet inhibitors or due to other coagulation abnormalities resulting from other anticoagulants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: March 2010
• Est. primary completion date: January 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• coronary artery bypass graft surgery with or without cardiopulmonary bypass

Exclusion Criteria:

• emergency; redo cardiac surgery; combined cardiac surgery; patients with renal insufficiency; patients with acquired coagulation abnormalities

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease

Intervention

Other:
• screening coagulation abnormalities
if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires Saint Luc	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

References & Publications (1)

Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ. Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting. Semin Thromb Hemost. 2005;31(4):426-40. — View Citation